Business
Arch Biopartners Announces Ethics Approval for St. Michael's Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide
TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or th...
About this update from Arch Biopartners, Inc.
[{"type":"text","content":"Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide\n\n\n\n TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) --\n \n Arch Biopartners Inc\n \n . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the University Health Network Research Ethics Board (“UHN REB”) has granted ethics approval for St. Michael’s Hospital, a site of Unity Health Toronto, to participate in Arch’s ongoing\n \n Phase II trial evaluating LSALT peptide\n \n for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).\n \n\n With the UHN REB approval, issued through the Clinical Trials Ontario (CTO) Stream system, St. Michael’s Hospital in Toronto, Ontario will now proceed to complete operational approvals, training, and site initiation before commencing patient enrollment. St. Michael’s Hospital will be the ninth site activated globally and the fourth site within one of Canada’s leading academic hospital networks.\n \n\n\n “Our research team is excited to be participating in this trial. Organ injury and repair is a Unity Health Toronto Research Pillar, and we are committed to investigating key mechanisms underlying tissue injury and healing, and to developing therapies to reduce injury and enhance regeneration,”\n \n said Dr. David Mazer, translational researcher, anesthesiologist and intensivist at St. Michael’s Hospital.\n \n\n The University Health Network’s Toronto General Hospital (Ontario) and the University of Calgary Cumming School of Medicine (Alberta) continue to actively enroll new patients in the trial. At Royal Columbian Hospital (British Columbia), the study team has recently received REB approval and is preparing for site initiation. Arch also continues to evaluate additional sites in Canada and the United States to join the CS-AKI Phase II trial.\n \n\n\n About the CS-AKI Phase II Trial\n \n\n\n The CS-AKI Phase II trial is an international, multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide with a recruitment target of 240 patients. Subjects are randomized to receive either LSALT peptide (10 mg IV twice daily for five days) or placebo, co...